zintick

Wave Life Sciences WVE

Wave Life Sciences, Inc. · Nasdaq · Pharmaceutical Preparations

$3.64+5.51%close on Oct. 28, 2026 · volume 4.3M · Yahoo Finance

Price, last 47 sessions

$4.00$5.00Sept. 2026Oct. 2026
Aug. 24, 2026 to Oct. 28, 2026 · high $5.25 · low $3.09 · SEC filing, placed when SEC released it

Our coverage

Nothing published yet.

Insider buying and selling

DateInsiderTradeSharesAvg. priceValue
Aug. 12, 2026Adrian Rawcliffe
director
Sold
10b5-1 plan
12,700$5.29$67,183
Aug. 11, 2026Heidi L. Wagner
director
Sold
10b5-1 plan
7,000$6.01$42,070
Aug. 11, 2026Ken Takanashi
director
Sold
10b5-1 plan
3,864$6.01$23,223
Aug. 11, 2026Aik Na Tan
director
Sold
10b5-1 plan
432$6.01$2,596

Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.

Recent SEC filings

All 19 →
  • SCHEDULE 13GOct. 27, 2026, 4:32 p.m. ETView on SEC.gov
  • SCHEDULE 13G/AOct. 27, 2026, 2:43 p.m. ETView on SEC.gov
  • 10-QOct. 27, 2026, 7:50 a.m. ETView on SEC.gov
  • 8-KOct. 27, 2026, 7:35 a.m. ETView on SEC.gov

    Results of operations and financial condition · Financial statements and exhibits

    AI summary, unreviewedWave Life Sciences Q3 2026 EPS of -$0.30 beats -$0.32 consensus, but revenue of $13.2 million tops the $4.4 million estimate; cash $431.0 million, runway into 3Q 2028

  • 4Oct. 7, 2026, 9:06 p.m. ETView on SEC.gov
  • 4Oct. 7, 2026, 9 p.m. ETView on SEC.gov
  • 4Oct. 7, 2026, 9 p.m. ETView on SEC.gov
  • 4Oct. 7, 2026, 9 p.m. ETView on SEC.gov